Loading...
XHKG
2170
Market cap80mUSD
Dec 05, Last price  
2.28HKD
1D
-1.30%
1Q
-33.14%
Name

Suzhou Basecare Medical Co Ltd

Chart & Performance

D1W1MN
XHKG:2170 chart
P/E
P/S
1.89
EPS
Div Yield, %
Shrs. gr., 5y
0.51%
Rev. gr., 5y
39.96%
Revenues
299m
+43.82%
32,609,00055,685,00081,109,000107,299,000140,901,000207,976,000299,109,000
Net income
-237m
L+23.66%
-154,877,000-531,336,000-877,052,000-143,651,000-123,163,000-191,685,000-237,029,000
CFO
-229m
L-14.26%
-26,695,000-38,145,000-64,288,000-197,852,000-188,769,000-267,234,000-229,116,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Suzhou Basecare Medical Corporation Limited, an investment holding company, engages in the research, development, manufacture, and provision of genetic testing solutions for assisted reproduction and sale of genetic testing devices and instruments in the People's Republic of China. The company offers genetic test kit products, which include pre-implantation genetic test kits, such as PGT-A to detect aneuploidy; PGT-M to detect single-gene or monogenic defects in pre-implantation embryos; and PGT-SR kits to detect chromosome structural rearrangements, which are common causes of recurrent miscarriage. It also provides prenatal test kit products comprising CNV kits; postnatal test kit products consist of WES kits; and devices and instruments, including liquid nitrogen storage dewar, cryostorage system, automated workstation, sperm quality analyzer, and NGS sequencer. The company also engages in the research, development, manufacture, and sale of medical devices and instruments. In addition, it provides marketing services; and engages in the research and development of software for medical devices and instruments. The company serves hospitals and reproductive clinics. Suzhou Basecare Medical Corporation Limited was incorporated in 2010 and is headquartered in Suzhou, China.
IPO date
Employees
479
Domiciled in
CN
Incorporated in

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT